<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27760" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Procainamide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pritchard</surname>
            <given-names>Brian</given-names>
          </name>
          <aff>The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thompson</surname>
            <given-names>Holly</given-names>
          </name>
          <aff>The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Pritchard declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Holly Thompson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27760.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Procainamide is a medication used to manage and treat ventricular arrhythmias, supraventricular arrhythmias, atrial flutter/fibrillation, and Wolf-Parkinson-White syndrome. It is in the antiarrhythmic Agent Class 1A class of medications. This activity reviews the indications, action, and contraindications for procainamide as a valuable agent in treating these arrhythmias.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of procainamide.</p></list-item><list-item><p>Describe the potential adverse effects of procainamide.</p></list-item><list-item><p>Review the appropriate monitoring of procainamide.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance the use of procainamide and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27760&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27760">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27760.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Procainamide is a medication used to manage and treat ventricular arrhythmias, supraventricular arrhythmias, atrial flutter, atrial fibrillation, AV nodal re-entrant tachycardia, and Wolf-Parkinson-White syndrome. It&#x000a0;is a Class 1A antiarrhythmic agent.&#x000a0; This activity reviews the literature, indications, action, and contraindications for procainamide as a valuable agent in the treatment of arrhythmias.</p>
        <p>Procainamide was initially approved by the US FDA in 1950 and fell out of favor due to its side effect profile and the development of newer antiarrhythmics. Procainamide usage has increased in recent years, and it is now seen as a viable option for several arrhythmias.</p>
        <p>Procainamide has been used for chemical cardioversion in atrial flutter and atrial fibrillation. These are&#x000a0;common arrhythmias seen in emergency department patients, but there is no consensus for optimal management. Stiell et al. looked at the usage of IV procainamide in 341 patients over five years. Adverse events were infrequent and included hypotension, bradycardia, atrioventricular block, and ventricular tachycardia. There were no cases of torsades de pointes, cerebrovascular accidents, or death. Most patients (94.4%) received a discharge to home. IV procainamide had a 52% conversion rate of atrial fibrillation to normal sinus&#x000a0;and a 28% conversion rate from atrial flutter to normal sinus.<xref ref-type="bibr" rid="article-27760.r1">[1]</xref></p>
        <p>One recent major study looked at the difference between amiodarone and procainamide in stable ventricular tachycardia. The PROCAMIO study has concluded that in patients with stable ventricular tachycardia, procainamide should be considered over the traditionally used amiodarone due to faster resolution of the arrhythmia, fewer major cardiac events, and is more efficacious in a subgroup of patients with structural heart disease.<xref ref-type="bibr" rid="article-27760.r2">[2]</xref></p>
        <p>Researchers have also studied the utility of procainamide compared to lidocaine in terminating sustained ventricular tachycardia in patients with structural heart defects. In this retrospective study from Circulation Journal, procainamide was found to be more effective than lidocaine in the termination of the arrhythmia.<xref ref-type="bibr" rid="article-27760.r3">[3]</xref></p>
        <p>Procainamide is indicated in patients with Wolf-Parkinson-White syndrome as it is important for acute termination of antidromic AV re-entrant tachycardia in stable patients. In particular, because the use of an AV nodal blocking agent in this patient population may enhance conduction down the accessory pathway and therefore induce ventricular tachycardia or ventricular fibrillation.<xref ref-type="bibr" rid="article-27760.r4">[4]</xref></p>
        <p>Procainamide has also historically been used in diagnostic testing for Brugada syndrome; this was known as the &#x0201c;procainamide challenge,&#x0201d; which produces the standard Brugada-like pattern on ECG, which may have been otherwise unnoticed and thus identifying patients at risk for sudden cardiac death. However, this usage has fallen out of favor, as it has low sensitivity for detecting Brugada-like patterns and may also put the patient at risk of going into ventricular arrhythmia.<xref ref-type="bibr" rid="article-27760.r5">[5]</xref></p>
      </sec>
      <sec id="article-27760.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Procainamide is a class 1A anti-arrhythmic that binds to fast sodium channels inhibiting recovery after repolarization. It also prolongs the action potential and reduces the speed of impulse conduction. This action results in decreased myocardial excitability, slowed conduction velocity, and reduced myocardial contractility. It is possible that it acts as a negative inotrope and may cause peripheral vasodilation and hypotension, which may require cardioversion.</p>
      </sec>
      <sec id="article-27760.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Procainamide is given IV or PO with the onset of action in 10&#x000a0;to 30 minutes. The loading dose is of IV procainamide is 10&#x000a0;to 17 mg/kg and administered at a rate of 20&#x000a0;to 50 mg/min. Alternatively, this may be dosed at 100 mg every 5 minutes in adult patients. The administration of this maintenance dose is from 1&#x000a0;to 4 mg/minute; however, the manufacturer labeling recommends 2 to 6 mg/minute.</p>
        <p>Administration of oral procainamide dosing for supraventricular arrhythmia is at 50 mg/kg/24 hours divided into doses every 6 hours.</p>
        <p>In the pediatric population, dosing divides into those less than 12 months in which a bolus dose of 7&#x000a0;to 10 mg/kg given over 15&#x000a0;to 30 minutes and those older than 12 months in which a bolus dose of 10 to 15 mg/kg is the regimen. An infusion rate of 20&#x000a0;to 50 mcg/kg/min follows the initial bolus.<xref ref-type="bibr" rid="article-27760.r6">[6]</xref></p>
        <p>Procainamide is metabolized hepatically via acetylation to form N-acetyl procainamide (NAPA) via a substrate of CYP2D6. This compound is then excreted as NAPA. The half-life of procainamide is 2.5 to 5 hrs, and the maximum dose in current recommendations is 17 mg/kg. As such, clinicians may consider decreasing the dosing or frequency of procainamide in cases of hepatic impairment.<xref ref-type="bibr" rid="article-27760.r7">[7]</xref></p>
      </sec>
      <sec id="article-27760.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects of procainamide include cardiac toxicity, bradycardia, hypotension, drug-induced lupus erythematosus-like syndrome, and blood dyscrasias. QRS, QTc, and PR prolongation are the most potentially harmful cardiac side effects of procainamide and may become worse when levels of procainamide rise. Serial electrocardiograms are useful for monitoring these toxic effects during treatment with procainamide. Procainamide infusion may also increase the number of premature ventricular contractions in patients.</p>
        <p>Another side effect of procainamide is hypotension, more commonly seen at doses of 20 mg/min.&#x000a0;Drug-induced lupus erythematosus-like syndrome is&#x000a0;rare and occurs due to the creation of positive ANA titers when taking the medication chronically. The symptoms of chronic use may include arthritis, arthralgias, and pleuritis&#x000a0;and commonly resolve when usage stops.</p>
        <p>Lastly, procainamide is known to cause certain blood dyscrasias. Procainamide has been known to cause bone marrow toxicity, leading to pancytopenia or agranulocytosis; this is usually due to hypersensitivity or varied immunologic mechanisms.<xref ref-type="bibr" rid="article-27760.r8">[8]</xref><xref ref-type="bibr" rid="article-27760.r9">[9]</xref></p>
      </sec>
      <sec id="article-27760.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Use with caution in patients with heart failure, electrolyte imbalances&#x000a0;(particularly hypokalemia and hypomagnesemia), myasthenia gravis patients, and in hepatic or renal impairment. Procainamide also crosses the placenta and may be present in the milk of breastfeeding mothers, and as such, chronic use requires caution in this population.<xref ref-type="bibr" rid="article-27760.r10">[10]</xref></p>
      </sec>
      <sec id="article-27760.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Procainamide monitoring during therapy of an acute arrhythmia should involve monitoring QRS duration via cardiac monitoring, and the clinician should stop therapy QRS increases by 50% of its original width. Also, blood pressure&#x000a0;requires frequent monitoring during treatment.</p>
      </sec>
      <sec id="article-27760.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity from procainamide overdose is rare as it is usually given IV in a monitored setting. However, it is plausible to administer a toxic dose accidentally or when a patient with renal impairment receives an inaccurate dose. Consultation of a medical toxicologist and regional poison control center is necessary in cases of oral procainamide overdose. Treatment would theoretically be similar to an overdose of other Class 1A antiarrhythmics, including quinidine and disopyramide, in which the patient receives hypertonic sodium bicarbonate to block sodium channels.<xref ref-type="bibr" rid="article-27760.r11">[11]</xref></p>
      </sec>
      <sec id="article-27760.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>There have been several high-quality studies as well as recommendations from the American Heart Association in utilizing procainamide as a viable option to terminate several different arrhythmias. However, procainamide should be used carefully in inpatient settings as it has several side effects that require monitoring. An interprofessional team that includes the treating physician, nurse, and pharmacist can help achieve the best possible outcomes. Care&#x000a0;requires coordination between&#x000a0;all interprofessional healthcare team members to ensure that everyone involved in the patient's care takes appropriate measures during therapy with procainamide. Cardiovascular monitoring, serial electrocardiograms, and frequent reassessments of the patient&#x02019;s clinical status will ensure safety during usage. Instruction should be given for possible cardioversion if hypotension, bradycardia, or clinical deterioration occurs.<xref ref-type="bibr" rid="article-27760.r12">[12]</xref>&#x000a0;[Level 1]</p>
        <p>The coordinated efforts of an interprofessional team will optimize therapeutic results with procainamide while minimizing adverse events. [Level 5]</p>
      </sec>
      <sec id="article-27760.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27760&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27760">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27760/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27760">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27760.s11">
        <title>References</title>
        <ref id="article-27760.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stiell</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Sivilotti</surname>
                <given-names>MLA</given-names>
              </name>
              <name>
                <surname>Taljaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Birnie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vadeboncoeur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hohl</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>McRae</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Brison</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Thiruganasambandamoorthy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Macle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Borgundvaag</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mercier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clement</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Brinkhurst</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sheehan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nemnom</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial.</article-title>
            <source>Lancet</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>395</volume>
            <issue>10221</issue>
            <fpage>339</fpage>
            <page-range>339-349</page-range>
            <pub-id pub-id-type="pmid">32007169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arribas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coll-Vinent</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Del Arco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peinado</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Almendral</surname>
                <given-names>J</given-names>
              </name>
              <collab>PROCAMIO Study Investigators</collab>
            </person-group>
            <article-title>Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.</article-title>
            <source>Eur Heart J</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>38</volume>
            <issue>17</issue>
            <fpage>1329</fpage>
            <page-range>1329-1335</page-range>
            <pub-id pub-id-type="pmid">27354046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Komura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chinushi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furushima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hosaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Iijima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yagihara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aizawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia.</article-title>
            <source>Circ J</source>
            <year>2010</year>
            <month>May</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>864</fpage>
            <page-range>864-9</page-range>
            <pub-id pub-id-type="pmid">20339190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <article-title>Correction to: 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Sep</month>
            <day>13</day>
            <volume>134</volume>
            <issue>11</issue>
            <fpage>e232</fpage>
            <page-range>e232-3</page-range>
            <pub-id pub-id-type="pmid">27619721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Obeyesekere</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Preventing Sudden Death in Asymptomatic Wolf-Parkinson-White Patients.</article-title>
            <source>JACC Clin Electrophysiol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>445</fpage>
            <page-range>445-447</page-range>
            <pub-id pub-id-type="pmid">30067482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guerrier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shamszad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Czosek</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Spar</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Knilans</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Variation in Antiarrhythmic Management of Infants Hospitalized with Supraventricular Tachycardia: A Multi-Institutional Analysis.</article-title>
            <source>Pediatr Cardiol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>946</fpage>
            <page-range>946-52</page-range>
            <pub-id pub-id-type="pmid">27033244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klotz</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Antiarrhythmics: elimination and dosage considerations in hepatic impairment.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2007</year>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>985</fpage>
            <page-range>985-96</page-range>
            <pub-id pub-id-type="pmid">18027986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawson</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Jick</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions to procainamide.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1977</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>507</fpage>
            <page-range>507-11</page-range>
            <pub-id pub-id-type="pmid">911600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Danielly</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>DeJong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Radke-Mitchell</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Uprichard</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Procainamide-associated blood dyscrasias.</article-title>
            <source>Am J Cardiol</source>
            <year>1994</year>
            <month>Dec</month>
            <day>01</day>
            <volume>74</volume>
            <issue>11</issue>
            <fpage>1179</fpage>
            <page-range>1179-80</page-range>
            <pub-id pub-id-type="pmid">7977085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pittard</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Glazier</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Procainamide excretion in human milk.</article-title>
            <source>J Pediatr</source>
            <year>1983</year>
            <month>Apr</month>
            <volume>102</volume>
            <issue>4</issue>
            <fpage>631</fpage>
            <page-range>631-3</page-range>
            <pub-id pub-id-type="pmid">6187910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Benowitz</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.</article-title>
            <source>Drug Saf</source>
            <year>1990</year>
            <season>Nov-Dec</season>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>393</fpage>
            <page-range>393-420</page-range>
            <pub-id pub-id-type="pmid">2285495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27760.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Group Members</collab>
              <name>
                <surname>January</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Furie</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>Heart Rhythm</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>e66</fpage>
            <page-range>e66-e93</page-range>
            <pub-id pub-id-type="pmid">30703530</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
